Osimertinib (OSI) is a mutant-selective EGFR inhibitor for the treatment of non-small cell lung cancer (NSCLC) harboring the T790M mutation, exhibiting effective antitumor activity17. This evidence concerns the gene EGFR and non-small cell lung carcinoma.